Distalmotion Secures Investment From J&J

Distalmotion, the Biopôle-based global MedTech company empowering access to robotic surgery in outpatient sites of care, announced a strategic investment from Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc (“JJDC”).

This investment follows the company’s successful 2025 closing of its $150M Series G round, led by Revival Healthcare Capital. Distalmotion focuses on the growing need for a purpose-built robotic platform designed for Ambulatory Surgery Centers (ASCs).

ASCs have emerged as the fastest growing US site of care segment in surgery. Preference for ASC convenience and quality, paired with payor policies that incentivize more cost-effective ASC-based care is driving the shift. As part of this dynamic, many ASCs are seeking to include soft tissue robotics in their surgical practice to support surgeon recruitment, patient attraction, and consistency of minimally invasive care.

DEXTER was developed with this outpatient setting in mind, purpose-built to meet the needs of busy ASCs with a small, mobile footprint, flexible workflows, open architecture, and instinctive design. In the US, DEXTER is cleared for use in adult inguinal hernia repair, cholecystectomy, and benign hysterectomy—three of the top five ambulatory procedures, representing more than 2.5M outpatient procedures¹.

“DEXTER is compatible with existing medical technology, including visualization systems and other devices used in minimally invasive surgery, and this investment is an important step as the US site of care shifts out of the hospital” said Greg Roche, CEO of Distalmotion. “It reflects a clear understanding that the soft tissue robotics market is becoming increasingly segmented. ASCs require an approach that balances performance with efficiency, and DEXTER was designed to serve that environment.”

DEXTER has been successfully integrated into clinical practice across Europe and the United States, with more than 3,000 patients treated to date. With strong clinical momentum and the strategic backing of JJDC and existing investors, including Revival Healthcare Capital, Distalmotion enters the new year focused on execution to support surgeons, providers, and health systems as robotic surgery scales across outpatient sites of care.

➡️ Source: Press Release | 📸 © Distalmotion